Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.

by David W Kang, Beate Bittner, Barry J Sugarman, Monica L Zepeda, Marie A Printz
Published 2021-01-01

A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration

by Robert J. Connor, Barbara Blouw, Jessica Cowell, Kelly Chen, Chunmei Zhao, David W. Kang
Published 2020-05-01

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

by Lavinia Morosi, Marina Meroni, Paolo Ubezio, Ilaria Fuso Nerini, Lucia Minoli, Luca Porcu, Nicolò Panini, Marika Colombo, Barbara Blouw, David W. Kang, Enrico Davoli, Massimo Zucchetti, Maurizio D’Incalci, Roberta Frapolli
Published 2021-09-01

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteer...

by Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD
Published 2020-01-01